Global Aflibercept Market
市场规模（十亿美元）
CAGR :
% 
 Forecast Period |
2022 –2029 |
 Market Size (Base Year) |
USD 8,343.15 Million |
 Market Size (Forecast Year) |
USD 13,911.94 Million |
 CAGR |
% |
| Major Markets Players |
|
全球阿柏西普市场，按类型（预充注射器包装和小瓶包装）、应用（湿性黄斑变性、转移性结直肠癌、糖尿病性黄斑水肿、糖尿病性视网膜病变、其他）、给药途径（静脉注射和玻璃体内注射）、最终用户（诊所、医院、诊断中心、其他）、分销渠道（医院药房、零售药房、网上药房）划分 - 行业趋势和预测到 2030 年。
阿柏西普市场分析和规模
阿柏西普是一种抗 VEGF 药物，主要用于治疗新生血管性年龄相关性黄斑变性 (wAMD) 和其他由视力障碍引起的视网膜病变。湿性黄斑变性、转移性结直肠癌、糖尿病性黄斑水肿引起的视力障碍和糖尿病性视网膜病变患病率的上升将促进市场增长。治疗疗法的进步和老年人口的增加是预计会增加阿柏西普市场增长的因素。政府资金和支持的增加也将扩大阿柏西普市场。
Data Bridge Market Research 分析称，2022 年阿柏西普市场规模为 83.4315 亿美元，到 2030 年将飙升至 139.1194 亿美元，预计在预测期内复合年增长率为 5.40%。这表明市场价值。由于对药物的需求不断增长，“医院”在阿柏西普市场的最终用户部分占据主导地位。除了对市场价值、增长率、细分、地理覆盖范围和主要参与者等市场情景的洞察外，Data Bridge Market Research 策划的市场报告还包括深度专家分析、患者流行病学、管道分析、定价分析和监管框架。
阿柏西普市场范围和细分
|
报告指标 |
细节 |
|
预测期 |
2023 至 2030 年 |
|
基准年 |
2022 |
|
历史岁月 |
2021 (可定制为 2014-2020) |
|
定量单位 |
收入（百万美元）、销量（单位）、定价（美元） |
|
涵盖的领域 |
类型（预充式注射器包装和小瓶包装）、用途（湿性黄斑变性、转移性结直肠癌、糖尿病性黄斑水肿、糖尿病性视网膜病变、其他）、给药途径（静脉注射和玻璃体内注射）、最终用户（诊所、医院、诊断中心、其他）、分销渠道（医院药房、零售药房、网上药房） |
|
覆盖国家 |
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America. |
|
Market Players Covered |
Bayer AG (Germany),Sanofi(France) ,Santen Pharmaceutical Co.,Ltd. (Japan), Regeneron Pharmaceuticals Inc.(U.S.), F. Hoffmann-La Roche Ltd. (U.S.),Amgen Inc. (U.S.),Pfizer, Inc. (U.S.), Xbrane Biopharma AB (Sweden),Allergan (Ireland), Viatris Inc. (U.S.) |
|
Market Opportunities |
|
Market Definition
Aflibercept is a vascular endothelial growth factor-A (VEGF-A) antagonist which is used for the treatment of neovascular (wet) age-related macular degeneration (AMD), diabetic retinopathy, and various types of muscular edema. It acts as a soluble decoy receptor which results in the binding of VEGF-A, VEGF-B, and placental growth factor (PIGF) and shows higher affinity. It is a medication which is traded under the brand names Eylea and Zaltrap.
Global Aflibercept Market Dynamics
Drivers
- Increasing prevalence of ophthalmic conditions
Growing cases of wet maculat degeneration, metastatic colorectal cancer, visual impairment due to diabetic macular edema, and diabetic retinopathy will lead to an increased sale of aflibercept.
According to the World Health Organization, AMD affects approximately 196 million people worldwide, with over 10.4 million cases involving moderate to severe vision impairment. AMD is an eye disease that causes progressive central vision loss and affects the elderly primarily.
- Rising number of geriatric population
Expanding geriatric population worldwide is predicted to favour aflibercept demand as this population is more prone to cause eye diseases. The number of persons above 65 years is projected to double to 1.5 billion in 2050. Colorectal cancer (CRC) is the second leading cause of cancer death in the US. Globally, there were over 1.8 million new cases in 2018. The prevalence of visual impairment among the aging population ranges from 22% to 35%.
- Advancement of therapies for the treatment
Advancement of therapies for the treatment are the expected factors that will increase the growth of aflibercept market. An alarming increase in the rate of eyes being nonpersistent to monitoring visits and therapy results in more demand. Moreover, it is anticipated that the market for anti-VEGF therapeutics will exhibit lucrative growth, as several market participants are focusing on R&D to develop novel treatments. Participants are actively engaged in extensive research and development to develop novel drugs to treat various eye disorders and gain a larger market share. As the number of individuals with diseases continues to rise at an alarming rate, there is a growing demand for novel therapies and treatments.
Opportunity
- Increase in government funds
Furthermore, increase in government funds and support for target research activities, growing clinical trials and rising product innovations and development owing to technological advancements all around the world will extend profitable opportunities for the market players in the forecast period of 2023 to 2030. Additionally, the expansion of money used by a country on its healthcare and its growth rate over the time is inclined by a wide variety of economic and social factors, including the financial agreements and structure of the organisation of the health system. This will further expand the market's growth rate in the future.
Restraints/Challenges
- Presence of other alternative medications
On the other hand, presence of other alternative medications and trade barriers are expected to obstruct market growth. Also, lack of favorable reimbursement scenario and technology penetration in the developing economies, are projected to challenge the market in the forecast period of 2023-2030.
This aflibercept market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the aflibercept market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Development
- In September 2022, Regeneron Pharmaceuticals, Inc. has announced that the primary endpoints were met in two pivotal trials investigating novel aflibercept 8 mg with 12- and 16-week dosing regimens in patients with diabetic macular edema (DME) and wet age-related macular degeneration (wAMD) on 12- and 16-week dosing intervals. This demonstrated that dosing regimens of the drugs based on which Regeneron and Bayer would submit these data to regulatory authorities in countries around the world.
全球阿柏西普市场范围
阿柏西普市场根据产品、应用、给药途径、最终用户和分销渠道进行细分。这些细分市场之间的增长将帮助您分析行业中增长微弱的细分市场，并为用户提供有价值的市场概览和市场洞察，帮助他们做出战略决策，确定核心市场应用。
产品
- 预充式注射器包装
- 小瓶包装
应用
- 湿性黄斑变性
- 转移性结直肠癌
- 糖尿病性黄斑水肿
- 糖尿病视网膜病变
- 其他的
给药途径
- 静脉
- 玻璃体内注射
终端用户
- 医院
- 诊所
- 诊断中心
- 其他的）
分销渠道
- 医院药房
- 零售药店
- 网上药店
全球阿柏西普市场区域分析/见解
对阿柏西普市场进行了分析，并按国家、产品、应用、给药途径、最终用户和分销渠道提供了市场规模洞察和趋势，如上所述。
阿柏西普市场报告涵盖的国家包括北美洲的美国、加拿大和墨西哥、欧洲的德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其、欧洲其他地区、中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、亚太地区 (APAC) 的其他地区、沙特阿拉伯、阿联酋、南非、埃及、以色列、中东和非洲 (MEA) 的其他地区、南美洲的巴西、阿根廷和南美洲其他地区。
由于主要关键参与者的存在、高患病率、不断增强的社会意识、发达的医疗保健行业以及政府对该地区研发的支持增加，北美在阿柏西普市场占据主导地位。
由于制药公司越来越关注治疗方法的进步、政府支持力度的加大以及医疗保健支出的不断增加，预计亚太地区将在 2023 年至 2030 年的预测期内实现最高增长率。
报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化会影响市场的当前和未来趋势。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测单个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。
医疗保健基础设施增长安装基础和新技术渗透
阿柏西普市场还为您提供每个国家/地区资本设备医疗保健支出增长、阿柏西普市场不同类型产品的安装基数、使用生命线曲线的技术影响以及医疗保健监管情景的变化及其对阿柏西普市场的影响的详细市场分析。数据涵盖 2010-2021 年的历史时期。
竞争格局和阿柏西普市场份额分析
阿柏西普市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对阿柏西普市场的关注有关。
阿柏西普市场的一些主要参与者包括：
- 拜耳公司（德国）
- 赛诺菲（法国）
- 参天制药株式会社（日本）
- Regeneron Pharmaceuticals Inc.（美国）
- F. Hoffmann-La Roche Ltd.（美国）
- 安进公司 (美国)
- 辉瑞公司（美国）
- Xbrane Biopharma AB（瑞典）
- 艾尔建（爱尔兰）
- Viatris Inc.（美国）
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
